In vitro and in vivo Effect of Antimicrobial Agent Combinations Against Carbapenem-Resistant Klebsiella pneumoniae with Different Resistance Mechanisms in China

References

• Centres for Disease Control and Prevention (US). Antibiotic Resistance Threats in the United States. Centers for Disease Control and Prevention; 2013.
   Google Scholar
• Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17(10):1791–1798. doi:10.3201/eid1710.11065522000347
   PubMed Web of Science ®Google Scholar
• Zhang R, Liu L, Zhou H, et al. Nationwide surveillance of clinical Carbapenem-resistant Enterobacteriaceae (CRE) strains in China. EBioMedicine. 2017;19:98–106. doi:10.1016/j.ebiom.2017.04.03228479289
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785–796. doi:10.1016/S1473-3099(13)70190-723969216
   PubMed Web of Science ®Google Scholar
• Fasciana T, Gentile B, Aquilina M, et al. Co-existence of virulence factors and antibiotic resistance in new Klebsiella pneumoniae clones emerging in south of Italy. BMC Infect Dis. 2019;19(1):928. doi:10.1186/s12879-019-4565-331684890
   PubMed Web of Science ®Google Scholar
• Wang X, Wang Q, Cao B, et al. Retrospective observational study from a chinese network of the impact of combination therapy versus monotherapy on mortality from Carbapenem-resistant Enterobacteriaceae Bacteremia. Antimicrob Agents Chemother. 2019;63(1).
   Web of Science ®Google Scholar
• Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943–950. doi:10.1093/cid/cis58822752516
   PubMed Web of Science ®Google Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58(4):2322–2328. doi:10.1128/AAC.02166-1324514083
   PubMed Web of Science ®Google Scholar
• Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother. 2014;58(2):654–663. doi:10.1128/AAC.01222-1324080646
   PubMed Web of Science ®Google Scholar
• Nath S, Moussavi F, Abraham D, Landman D, Quale J. In vitro and in vivo activity of single and dual antimicrobial agents against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2017;73(2):431–436. doi:10.1093/jac/dkx419
   Web of Science ®Google Scholar
• Lawandi A, Leite G, Cheng MP, Lefebvre B, Longtin J, Lee TC. In vitro synergy of β-lactam combinations against KPC-producing Klebsiella pneumoniae strains. J Antimicrob Chemother. 2019;74(12):3515–3520. doi:10.1093/jac/dkz38931730163
   PubMed Web of Science ®Google Scholar
• Hagiya H, Aoki K, Akeda Y, et al. In vitro effectiveness of meropenem and cefmetazole combination treatment against KPC-2-producing enterobacteriaceae. Microbial Drug Resist (Larchmont, NY). 2019;25(6):839–845. doi:10.1089/mdr.2018.0397
   Web of Science ®Google Scholar
• Krezdorn J, Adams S, Coote PJ. A Galleria mellonella infection model reveals double and triple antibiotic combination therapies with enhanced efficacy versus a multidrug-resistant strain of Pseudomonas aeruginosa. J Med Microbiol. 2014;63(7):945–955. doi:10.1099/jmm.0.074245-024928215
   PubMed Web of Science ®Google Scholar
• Wand ME, McCowen JWI, Nugent PG, Sutton JM. Complex interactions of Klebsiella pneumoniae with the host immune system in a Galleria mellonella infection model. J Med Microbiol. 2013;62(12):1790–1798. doi:10.1099/jmm.0.063032-024000226
   PubMed Web of Science ®Google Scholar
• Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70(1):119–123. doi:10.1016/j.diagmicrobio.2010.12.00221398074
   PubMed Web of Science ®Google Scholar
• Landman D, Bratu S, Quale J. Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae. J Med Microbiol. 2009;58(10):1303–1308. doi:10.1099/jmm.0.012575-019556371
   PubMed Web of Science ®Google Scholar
• Zhou M, Wang D, Kudinha T, Yang Q, Yu S, Xu YC. Comparative evaluation of four phenotypic methods for detection of class A and B carbapenemase-producing enterobacteriaceae in China. J Clin Microbiol. 2018;56(8). doi:10.1128/JCM.00395-18
   Web of Science ®Google Scholar
• CLSI. Performance Standards for Antimicrobial Susceptibility Testing Twenty-Second Informational Supplement M100-S21. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
   Google Scholar
• Bae S, Kim MC, Park SJ, et al. In vitro synergistic activity of antimicrobial agents in combination against clinical isolates of colistin-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60(11):6774–6779. doi:10.1128/AAC.00839-1627600048
   PubMed Web of Science ®Google Scholar
• Bai Y, Liu B, Wang T, et al. In Vitro activities of combinations of rifampin with other antimicrobials against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59(3):1466–1471. doi:10.1128/AAC.04089-1425534730
   PubMed Web of Science ®Google Scholar
• Albur M, Noel A, Bowker K, MacGowan A. Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2012;56(6):3441–3443. doi:10.1128/AAC.05682-1122391543
   PubMed Web of Science ®Google Scholar
• Alhadab AA, Ahmed MA, Brundage RC. Amikacin pharmacokinetic-pharmacodynamic analysis in pediatric cancer patients. Antimicrob Agents Chemother. 2018;62(4). doi:10.1128/AAC.01781-17
   Web of Science ®Google Scholar
• Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther. 2008;30(1):143–151. doi:10.1016/j.clinthera.2008.01.01518343250
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006;58(6):1221–1229. doi:10.1093/jac/dkl40317012300
   PubMed Web of Science ®Google Scholar
• Gaibani P, Lombardo D, Lewis RE, et al. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. J Antimicrob Chemother. 2014;69(7):1856–1865. doi:10.1093/jac/dku06524648503
   PubMed Web of Science ®Google Scholar
• Cebrero-Cangueiro T, Álvarez-Marín R, Labrador-Herrera G, et al. In vitro activity of pentamidine alone and in combination with aminoglycosides, tigecycline, rifampicin, and doripenem against clinical strains of carbapenemase-producing and/or Colistin-resistant Enterobacteriaceae. Front Cell Infect Microbiol. 2018;8:363. doi:10.3389/fcimb.2018.0036330406040
   PubMed Web of Science ®Google Scholar
• Champion OL, Titball RW, Bates S. Standardization of G. mellonella larvae to provide reliable and reproducible results in the study of fungal pathogens. J Fungi (Basel, Switzerland). 2018;4(3). doi:10.3390/jof4030108
   Google Scholar
• Benthall G, Touzel RE, Hind CK, et al. Evaluation of antibiotic efficacy against infections caused by planktonic or biofilm cultures of Pseudomonas aeruginosa and Klebsiella pneumoniae in Galleria mellonella. Int J Antimicrob Agents. 2015;46(5):538–545. doi:10.1016/j.ijantimicag.2015.07.01426364845
   PubMed Web of Science ®Google Scholar
• Betts JW, Phee LM, Hornsey M, Woodford N, Wareham DW. In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2014;58(6):3541–3546. doi:10.1128/AAC.02449-1424687491
   PubMed Web of Science ®Google Scholar
• Donadu MG, Trong LN, Viet HD, et al. Phytochemical compositions and biological activities of essential oils from the leaves, rhizomes and whole plant of hornstedtia bella škorničk. Antibiotics (Basel, Switzerland). 2020;9(6).
   Web of Science ®Google Scholar
• Usai D, Donadu M, Bua A, et al. Enhancement of antimicrobial activity of pump inhibitors associating drugs. J Infect Dev Ctries. 2019;13(2):162–164. doi:10.3855/jidc.1110232036352
   PubMed Web of Science ®Google Scholar
• Mohamed SH, Mohamed MSM, Khalil MS, Azmy M, Mabrouk MI. Combination of essential oil and ciprofloxacin to inhibit/eradicate biofilms in multidrug-resistant Klebsiella pneumoniae. J Appl Microbiol. 2018;125(1):84–95. doi:10.1111/jam.1375529517825
   PubMed Web of Science ®Google Scholar
• Trong LN, Viet HD, Quoc Doan T, et al. Biological activities of essential oils from leaves of Paramignya trimera (Oliv.) Guillaum and Limnocitrus littoralis (Miq.) swingle. Antibiotics (Basel, Switzerland). 2020;9(4).
   Web of Science ®Google Scholar
• Schultsz C, Geerlings S. Plasmid-mediated resistance in enterobacteriaceae: changing landscape and implications for therapy. Drugs. 2012;72(1):1–16. doi:10.2165/11597960-000000000-00000
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Tumbarello M. Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. Virulence. 2017;8(4):470–484. doi:10.1080/21505594.2017.129219628276996
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Q, Yin Y, et al. Epidemiology of Carbapenem-resistant Enterobacteriaceae infections: report from the China CRE network. Antimicrob Agents Chemother. 2018;62(2).
   Web of Science ®Google Scholar
• Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother. 2006;57(3):573–576. doi:10.1093/jac/dki47716431863
   PubMed Web of Science ®Google Scholar
• Zhang J, Yu L, Fu Y, et al. Tigecycline in combination with other antibiotics against clinical isolates of carbapenem-resistant Klebsiella pneumoniae in vitro. Ann Palliat Med. 2019;8(5):622–631. doi:10.21037/apm.2019.09.1131735038
   PubMed Web of Science ®Google Scholar
• Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN. Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010–2013). Diagn Microbiol Infect Dis. 2015;83(2):183–186. doi:10.1016/j.diagmicrobio.2015.06.01126164275
   PubMed Web of Science ®Google Scholar
• Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56(4):2108–2113. doi:10.1128/AAC.06268-1122252816
   PubMed Web of Science ®Google Scholar
• Zarkotou O, Pournaras S, Voulgari E, et al. Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study. J Clin Microbiol. 2010;48(6):2271–2274. doi:10.1128/JCM.02301-0920375234
   PubMed Web of Science ®Google Scholar
• Bi S, Yao X, Huang C, et al. Antagonistic effect between tigecycline and meropenem: successful management of KPC-producing Klebsiella pneumoniae infection. Infection. 2019;47(3):497–500. doi:10.1007/s15010-019-01274-w30734249
   PubMed Web of Science ®Google Scholar
• Logan LK, Weinstein RA. The epidemiology of Carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S28–s36. doi:10.1093/infdis/jiw28228375512
   PubMed Web of Science ®Google Scholar
• Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10(9):597–602. doi:10.1016/S1473-3099(10)70143-220705517
   PubMed Web of Science ®Google Scholar
• Franceschini N, Caravelli B, Docquier JD, et al. Purification and biochemical characterization of the VIM-1 metallo-beta-lactamase. Antimicrob Agents Chemother. 2000;44(11):3003–3007. doi:10.1128/AAC.44.11.3003-3007.200011036013
   PubMed Web of Science ®Google Scholar
• Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol. 2010;8(6):423–435. doi:10.1038/nrmicro233320440275
   PubMed Web of Science ®Google Scholar
• Ramirez MS, Tolmasky ME. Amikacin: uses, resistance, and prospects for inhibition. Molecules (Basel, Switzerland). 2017;22(12):2267. doi:10.3390/molecules22122267
   PubMed Web of Science ®Google Scholar